PsoProtect is an international registry developed to enable clinicians to report outcomes of COVID-19 in individuals with psoriasis. It is hoped that PsoProtect will help us to understand how immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis and it will provide real-time updates on cases reported for the benefit of the dermatology community. PsoProtect seeks to improve our understanding of how factors such as immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis.
IPC is pleased to be part of this important initiative and asks if you have a psoriasis patient diagnosed with COVID-19, please contribute to this important registry by submitting your case using the online PsoProtect case report form.
In addition, an adjoining registry PsoProtectMe has been set up for patients to self-report their experiences.
View the current data. You can also view our summary of the data collected from the first 50 cases, 200 cases, 1002 cases, 1118 cases.
WATCH NOW Catherine Smith, MD, and Savteer Mahil, MD, talk to IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD, about their goals for the PsoProtect patient registry to study COVID-19 and psoriasis.
Latest news European Commission approves SKYRIZI® for psoriatic arthritis in adultsNovember 22, 2021The European Commission has approved SKYRIZI® for the treatment of active psoriatic arthritis in adults. Focus on Psoriasis – A Report from the 2021 Virtual EADV CongressNovember 18, 2021The European Academy of Dermatology and Venerelogy 30th Annual Congress (EADV) was packed with science and clinical practice updates. You can download the full report or read a brief look at some of the highlights. PsoProtect Registry Data UpdateNovember 04, 2021PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,272 cases. Update on spesolimab for generalized pustular psoriasisNovember 02, 2021The European Medicines Agency (EMA) has accepted to review Boehringer Ingelheim’s marketing authorization application (MAA) for spesolimab to treat flares in generalised pustular psoriasis (GPP). More News
